We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+0.96%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.07B
AUM Growth
+$361M
Cap. Flow
+$391M
Cap. Flow %
18.88%
Top 10 Hldgs %
46.93%
Holding
58
New
10
Increased
9
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$105M
2
GILD icon
Gilead Sciences
GILD
+$66.6M
3
CI icon
Cigna
CI
+$66M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$64M
5
PRGO icon
Perrigo
PRGO
+$59M

Top Sells

Rank Stock Value
1
STJ
St Jude Medical
STJ
+$68.8M
2
ABBV icon
AbbVie
ABBV
+$51.4M
3
DGX icon
Quest Diagnostics
DGX
+$42.9M
4
MASI
Masimo
MASI
+$41.8M
5
NUVA
NuVasive, Inc.
NUVA
+$40.5M

Sector Composition

Rank Sector Weight
1 Healthcare 64.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELGX
26
DELISTED
Endologix Inc
ELGX
$37.4M 1.81%
300,000
-86,450
-22% -$9.94M
BHC icon
27
Bausch Health
BHC
$2.49B
$33.4M 1.61%
1,656,000
-344,000
-17% -$9.74M
THC icon
28
Tenet Healthcare
THC
$20.4B
$31.1M 1.5%
1,125,000
-375,000
-25% -$11.1M
ARIA
29
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$29.6M 1.43%
4,000,000
-1,405,235
-26% -$10.5M
OPCH icon
30
Option Care Health
OPCH
$3.41B
$26M 1.25%
2,545,000
+1,000,000
+65% +$10.2M
NVTA
31
DELISTED
Invitae Corporation
NVTA
$20.3M 0.98%
2,746,622
– –
ELOS
32
DELISTED
Syneron Medical Ltd
ELOS
$18.1M 0.87%
2,347,593
+841,893
+56% +$6M
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
$18M 0.87%
+1,050,000
New +$18.8M
SQNM
34
DELISTED
SEQUENOM INC NEW
SQNM
$15.8M 0.77%
17,325,000
– –
AMAG
35
DELISTED
AMAG Pharmaceuticals
AMAG
$14.4M 0.69%
600,000
– –
PTCT icon
36
PTC Therapeutics
PTCT
$5.7B
$10.5M 0.51%
1,500,000
+606,100
+68% +$4.45M
PLX icon
37
Protalix BioTherapeutics
PLX
$181M
$8.5M 0.41%
1,327,500
– –
DRRX
38
DELISTED
DURECT Corp
DRRX
$7.32M 0.35%
600,000
– –
BIOL
39
DELISTED
Biolase, Inc.
BIOL
$6.24M 0.3%
427
– –
GNMK
40
DELISTED
GenMark Diagnostics, Inc
GNMK
$5.65M 0.27%
649,097
– –
OSUR icon
41
OraSure Technologies
OSUR
$270M
$4.18M 0.2%
707,559
-1,292,441
-65% -$9.19M
ATXS
42
DELISTED
Astria Therapeutics
ATXS
$3.7M 0.18%
16,667
– –
DXTR
43
DELISTED
Dextera Surgical Inc.
DXTR
$1.51M 0.07%
+837,483
New +$1.72M
EPRS
44
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$835K 0.04%
1,847,500
– –
ABBV icon
45
AbbVie
ABBV
$447B
– –
-900,000
Closed -$51.4M
ANGO icon
46
AngioDynamics
ANGO
$610M
– –
-243,183
Closed -$2.99M
DGX icon
47
Quest Diagnostics
DGX
$25.8B
– –
-600,000
Closed -$42.9M
MASI
48
DELISTED
Masimo
MASI
– –
-1,000,000
Closed -$41.8M
STJ
49
DELISTED
St Jude Medical
STJ
– –
-1,250,000
Closed -$68.8M
CRDC
50
DELISTED
CARDICA INC COM NEW (DE)
CRDC
– –
-837,483
Closed -$2.98M
1
2
3

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Camber Capital Management held 58 positions worth $2.07B, up 21% from $1.71B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Camber Capital Management deployed $391M of net new capital in Q2 2016, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Endo International plc: 5,045,000 shares worth $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 69% a quarter earlier.

On the sell side, the largest reduction was NuVasive, Inc., an estimated $40.5M trimmed.

  • Camber Capital Management's largest Q2 2016 buy was Endo International plc: 5,045,000 shares worth $78.7M.
  • Camber Capital Management added most to Viatris in Q2 2016, an estimated $39.4M increase.
  • Camber Capital Management's biggest Q2 2016 reduction was NuVasive, Inc., cutting an estimated $40.5M.
  • Camber Capital Management fully exited St Jude Medical in Q2 2016, selling an estimated $68.8M.
  • Camber Capital Management's ten largest holdings make up 47% of its $2.07B portfolio in Q2 2016.
  • Camber Capital Management opened 10 new positions and closed 10 in Q2 2016.
  • Camber Capital Management's portfolio value rose 21% quarter-over-quarter to $2.07B.

Based on Camber Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.